External broker reports(aggregated public sources), HDFC Securities

HDFC Securities

HDFC securities is the best online trading platform for stocks, IPOs, mutual fund in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

HDFC securities is the best online trading platform for stocks, IPOs, mutual fund in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Thematic (Sector/Industry)

India Utilities / Thematic (Sector/Industry)

<ul><li>Oil India: Our BUY recommendation on Oil India with a revised target price of INR 490 is premised on oil production growth at 10% CAGR and gas production growth at 21% CAGR over FY25-27E</li><li>Q4FY25 standalone EBITDA at INR 19.8bn (-15% YoY, -7% QoQ) and PAT at INR 15.9bn (-21.6% YoY, +30.3% QoQ) came in below our estimates due to lower-than-expected volume and higher opex</li><li>Oil and gas production stood at 1.65mmtoe (-0.2%YoY, -2.8% QoQ). Medplus Health Services: EBITDA^ grew 29% YoY despite muted sales (pharmacy +1% YoY, diagnostics +21% YoY) and higher staff costs (+21%), led by 398 bps YoY expansion in gross margin (driven by increased private label share to 23.3%) and flat SG&amp;A</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Oil India: Our BUY recommendation on Oil India with a revised target price of INR 490 is premised on oil production growth at 10% CAGR and gas production growth at 21% CAGR over FY25-27EQ4FY25 standalone EBITDA at INR 19.8bn (-15% YoY, -7% QoQ) and PAT at INR 15.9bn (-21.6% YoY, +30.3% QoQ) came in below our estimates due to lower-than-expected volume and higher opexOil and gas production stood at 1.65mmtoe (-0.2%YoY, -2.8% QoQ). Medplus Health Services: EBITDA^ grew 29% YoY despite muted sales (pharmacy +1% YoY, diagnostics +21% YoY) and higher staff costs (+21%), led by 398 bps YoY expansion in gross margin (driven by increased private label share to 23.3%) and flat SG&amp;AContent is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

HSIE決算発表：オイル・インディア、メドプラス・ヘルス・サービス、JKラクシュミ・セメント、サンセラ・エンジニアリング